Rothwell B, Sheikh K, Knight C, Kamgar F, Jain R, Mamtani R, Kurt M, Poretta T, Broughton E, Teitsson S. Cost-utility of Nivolumab versus observation for the adjuvant treatment of Urothelial Carcinoma (UC) for patients who are at high-risk of recurrence: a United States (US) payer perspective. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun;.
Kamgar F, Hughes R, Lucherini S. Developing a predictive algorithm to identify the key factors impacting on the transmission and fatalities from COVID-19. Value Health. 2021 Jun 1;24(Suppl 1):S114. doi: 10.1016/j.jval.2021.04.1237